biostudies-literatureUnknown12(12)Iida Y<h4>Background</h4>Immune checkpoint blockade is a promising anticancer therapy, whereas the presence of T cells in tumor sites is indispensable for its therapeutic efficacy. To promote the infiltration of T cells and dendritic cells (DCs) into the tumor, we previously proposed a local cell therapy using chemokine (C-C motif) ligand 19 (CCL19)-expressing immortalized syngeneic immortalized mesenchymal stem cells (syn-iMSC/CCL19). However, the preparation of syngeneic/autologous MSC from individual hosts limits the clinical application of this cell therapy.<h4>Methods</h4>In this study, we further developed a new cell therapy using allogeneic iMSC/CCL19 (allo-iMSC/CCL19) using several tumor mice models.<h4>Results</h4>The allo-iMSC/CCL19 therapy exerted drastic antitumor effects, in which tJournal for immunotherapy of cancere009683https://www.ebi.ac.uk/biostudies/studies/S-EPMC11647367biostudies-literatureLocal cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103&lt;sup&gt;+&lt;/sup&gt; IL-12-producing dendritic cells and priming CD8&lt;sup&gt;+&lt;/sup&gt; T cells without involving draining lymph nodes.PMC11647367Harada MIida YfalseLocal cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103&lt;sup&gt;+&lt;/sup&gt; IL-12-producing dendritic cells and priming CD8&lt;sup&gt;+&lt;/sup&gt; T cells without involving draining lymph nodes.<h4>Background</h4>Immune checkpoint blockade is a promising anticancer therapy, whereas the presence of T cells in tumor sites is indispensable for its therapeutic efficacy. To promote the infiltration of T cells and dendritic cells (DCs) into the tumor, we previously proposed a local cell therapy using chemokine (C-C motif) ligand 19 (CCL19)-expressing immortalized syngeneic immortalized mesenchymal stem cells (syn-iMSC/CCL19). However, the preparation of syngeneic/autologous MSC from individual hosts limits the clinical application of this cell therapy.<h4>Methods</h4>In this study, we further developed a new cell therapy using allogeneic iMSC/CCL19 (allo-iMSC/CCL19) using several tumor mice models.<h4>Results</h4>The allo-iMSC/CCL19 therapy exerted drastic antitumor effects, in which t2024-01-01T00:00:00Z2024 Dec2025-04-04T01:31:05.238Z2025-04-04T01:31:05.238ZS-EPMC116473673967255310.1136/jitc-2024-009683